Business
Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or th...
About this update from Arch Biopartners, Inc.
[{"type":"text","content":"Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia\n\n\n\n TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) --\n \n Arch Biopartners Inc\n \n . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Research Ethics Board (“REB”) has granted approval for the Royal Columbian Hospital (RCH) to participate in Arch’s ongoing\n \n Phase II trial evaluating LSALT peptide\n \n for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).\n \n\n With this ethics approval in place, the clinical team at RCH in New Westminster, British Columbia, will proceed to complete operational approvals, training, and site initiation prior to commencing patient enrollment. RCH will be the eighth site activated globally in the study and is expected to be the fourth site to recruit patients in Canada.\n \n\n The University Health Network’s Toronto General Hospital and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial. Unity Health’s St. Michael’s Hospital has completed its preparatory steps and is awaiting final authorization from Clinical Trials Ontario (CTO) to proceed to site activation and patient enrollment. The Arch team continues to evaluate additional sites in Canada and the U.S. to join the CS-AKI Phase II trial.\n \n\n\n Other Company News\n \n\n\n The TSX Venture Exchange has granted final approval for the Company’s acquisition of Lipdro Therapeutics Inc. in exchange for 250,000 common shares of Arch and a royalty on future net sales of specific chronic kidney disease (CKD) drug candidates derived from the newly acquired CKD platform targeting IL-32. The acquisition of the CKD platform and Lipdro Therapeutics was first disclosed by the Company in a press release issued on September 17, 2025.\n \n\n In addition, the Board of Directors of the Company has granted a total of 750,000 stock options to directors and officers pursuant to the Company’s stock option plan and the requirements of the TSX Venture Exchange. Each of these stock options is exercisable into one common share of the Company at a price of $1.70 per share for a period of ten years, effective Nove...